IS5708A - Mótefni gegn ED-B svæði fibrónektíns, samsett efni, sem innihalda þau, og notkun þeirra til að sjúkdómsgreina og meðhöndla æxli og sjúkdóma, sem tengjast æðanýmyndun - Google Patents
Mótefni gegn ED-B svæði fibrónektíns, samsett efni, sem innihalda þau, og notkun þeirra til að sjúkdómsgreina og meðhöndla æxli og sjúkdóma, sem tengjast æðanýmyndunInfo
- Publication number
- IS5708A IS5708A IS5708A IS5708A IS5708A IS 5708 A IS5708 A IS 5708A IS 5708 A IS5708 A IS 5708A IS 5708 A IS5708 A IS 5708A IS 5708 A IS5708 A IS 5708A
- Authority
- IS
- Iceland
- Prior art keywords
- antibodies
- fibronectin
- vasculitis
- diagnose
- region
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7533898A | 1998-05-11 | 1998-05-11 | |
US09/300,425 US20030045681A1 (en) | 1998-05-11 | 1999-04-28 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
PCT/EP1999/003210 WO1999058570A2 (en) | 1998-05-11 | 1999-05-11 | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
IS5708A true IS5708A (is) | 2000-11-10 |
IS2522B IS2522B (is) | 2009-07-15 |
Family
ID=26756726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS5708A IS2522B (is) | 1998-05-11 | 2000-11-10 | Mótefni fyrir ED-B-hneppi fibrónektíns, samsetningar, sem innihalda þau, og notkun þeirra til þess að sjúkdómsgreina og til þess að meðhöndla æxli og sjúkdóma, sem tengjast æðanýmyndun |
Country Status (24)
Country | Link |
---|---|
US (1) | US20070189963A1 (is) |
EP (1) | EP1084145B1 (is) |
JP (1) | JP2002514405A (is) |
CN (1) | CN1250571C (is) |
AT (1) | ATE301676T1 (is) |
AU (1) | AU759207B2 (is) |
BR (1) | BRPI9910394B8 (is) |
CA (1) | CA2333833C (is) |
CZ (1) | CZ300495B6 (is) |
DE (1) | DE69926630T2 (is) |
DK (1) | DK1084145T3 (is) |
EA (1) | EA005685B1 (is) |
EE (1) | EE05435B1 (is) |
ES (1) | ES2247802T3 (is) |
HU (1) | HU225675B1 (is) |
IL (1) | IL139452A0 (is) |
IS (1) | IS2522B (is) |
NO (1) | NO327732B1 (is) |
NZ (1) | NZ508600A (is) |
PL (1) | PL199353B1 (is) |
SK (1) | SK286822B6 (is) |
TR (1) | TR200003317T2 (is) |
TW (1) | TWI259837B (is) |
WO (1) | WO1999058570A2 (is) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
DE69932084T2 (de) * | 1999-01-05 | 2007-06-28 | The Flinders University Of South Australia, Bedford Park | Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
ATE526039T1 (de) | 2000-02-24 | 2011-10-15 | Philogen Spa | Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
DE10045803A1 (de) * | 2000-09-07 | 2002-04-11 | Schering Ag | Rezeptor der EDb Fibronektin-Domäne |
PL364358A1 (en) * | 2000-09-07 | 2004-12-13 | Schering Ag | Receptor in the edb fibronectin domain (ii) |
US20030100010A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Fibrinogen biopolymer Marker predictive of type II diabetes |
JP2005538033A (ja) * | 2001-12-04 | 2005-12-15 | ナノスペクトラ バイオサイエンセズ,インク. | 過剰なあるいは不適切な新脈管形成によって特徴付けられる病状の治療 |
AU2003210149B2 (en) * | 2002-01-03 | 2008-10-09 | Bayer Schering Pharma Aktiengesellschaft | Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours |
SI1461360T1 (sl) * | 2002-01-03 | 2010-12-31 | Bayer Schering Pharma Ag | Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev |
WO2003076469A2 (en) * | 2002-03-11 | 2003-09-18 | Philogen S.P.A. | Antibodies derived rom anti ed-b l19 and targeting tumor vasculature |
CN104225610B (zh) | 2002-07-15 | 2017-03-01 | 得克萨斯大学体系董事会 | 与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗用途 |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
WO2007056441A2 (en) * | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1945767B1 (de) * | 2005-11-09 | 2010-04-07 | MorphoSys AG | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern |
EP1842553A1 (en) * | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
ATE548052T1 (de) | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
JP2009244154A (ja) | 2008-03-31 | 2009-10-22 | Nationa Hospital Organization | 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法 |
EP2116555A1 (en) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
WO2010056889A2 (en) * | 2008-11-12 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Use of an antibody and a rare-earth based crystal |
BR112012014194A2 (pt) | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
WO2011110490A1 (en) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
WO2012172055A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Dimeric binding proteins based on modified ubiquitins |
WO2013010749A1 (en) | 2011-07-19 | 2013-01-24 | Philogen S.P.A | Sequential anti - ctla4 and targeted il-2 therapy |
RU2481839C2 (ru) * | 2011-08-16 | 2013-05-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" | Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий |
WO2013186329A1 (en) | 2012-06-13 | 2013-12-19 | Scil Proteins Gmbh | Human fusion proteins comprising single chain tnfalpha and targeting domains |
WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
WO2014194784A1 (zh) * | 2013-06-06 | 2014-12-11 | 合肥立方制药股份有限公司 | 人源抗纤连蛋白ed-b结构域的抗体及其用途 |
CA2975362A1 (en) | 2015-02-06 | 2016-08-11 | Navigo Proteins Gmbh | Egfr binding proteins comprising ubiquitin muteins |
KR102064396B1 (ko) | 2015-07-16 | 2020-01-09 | 나피고 프로타인스 게엠베하 | 신규한 면역글로불린-결합 단백질 및 친화도 정제에서의 이의 용도 |
US10584152B2 (en) | 2015-07-20 | 2020-03-10 | Navigo Proteins Gmbh | Binding proteins based on di-ubiquitin muteins and methods for generation |
EP3378947B1 (en) * | 2015-11-16 | 2024-01-24 | Hefei Lifeon Pharmaceutical Co. Ltd. | Use of ed-b protein in diagnosis of tissue hyperplasia |
CA3022751A1 (en) | 2016-05-04 | 2017-11-09 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
KR102578256B1 (ko) | 2016-08-11 | 2023-09-15 | 리플리겐 코포레이션 | 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질 |
SG11201903400WA (en) | 2016-10-17 | 2019-05-30 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
CN111148759B (zh) | 2017-09-30 | 2023-09-19 | 合肥立方制药股份有限公司 | 结合至纤维连接蛋白b结构域的蛋白 |
EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
AU2022296794A1 (en) | 2021-06-23 | 2023-12-14 | Cytune Pharma | Interleukin-15 based immunocytokines |
CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
CA3242326A1 (en) | 2022-01-04 | 2023-07-13 | Cipo | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
WO2024028258A1 (en) | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
WO2024047237A1 (en) | 2022-09-01 | 2024-03-07 | Philogen S.P.A. | Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
-
1999
- 1999-05-10 TW TW088107648A patent/TWI259837B/zh active
- 1999-05-11 EA EA200001169A patent/EA005685B1/ru not_active IP Right Cessation
- 1999-05-11 DE DE69926630T patent/DE69926630T2/de not_active Expired - Lifetime
- 1999-05-11 JP JP2000548372A patent/JP2002514405A/ja active Pending
- 1999-05-11 HU HU0102992A patent/HU225675B1/hu not_active IP Right Cessation
- 1999-05-11 AU AU40398/99A patent/AU759207B2/en not_active Expired
- 1999-05-11 TR TR2000/03317T patent/TR200003317T2/xx unknown
- 1999-05-11 EP EP99923571A patent/EP1084145B1/en not_active Expired - Lifetime
- 1999-05-11 CA CA2333833A patent/CA2333833C/en not_active Expired - Lifetime
- 1999-05-11 WO PCT/EP1999/003210 patent/WO1999058570A2/en active IP Right Grant
- 1999-05-11 ES ES99923571T patent/ES2247802T3/es not_active Expired - Lifetime
- 1999-05-11 IL IL13945299A patent/IL139452A0/xx unknown
- 1999-05-11 BR BRPI9910394 patent/BRPI9910394B8/pt not_active IP Right Cessation
- 1999-05-11 EE EEP200000802A patent/EE05435B1/xx not_active IP Right Cessation
- 1999-05-11 PL PL345845A patent/PL199353B1/pl not_active IP Right Cessation
- 1999-05-11 NZ NZ508600A patent/NZ508600A/xx unknown
- 1999-05-11 CN CNB998060526A patent/CN1250571C/zh not_active Expired - Lifetime
- 1999-05-11 SK SK1679-2000A patent/SK286822B6/sk not_active IP Right Cessation
- 1999-05-11 DK DK99923571T patent/DK1084145T3/da active
- 1999-05-11 AT AT99923571T patent/ATE301676T1/de active
- 1999-05-11 CZ CZ20004216A patent/CZ300495B6/cs not_active IP Right Cessation
-
2000
- 2000-11-10 NO NO20005694A patent/NO327732B1/no not_active IP Right Cessation
- 2000-11-10 IS IS5708A patent/IS2522B/is unknown
-
2006
- 2006-12-13 US US11/637,810 patent/US20070189963A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS5708A (is) | Mótefni gegn ED-B svæði fibrónektíns, samsett efni, sem innihalda þau, og notkun þeirra til að sjúkdómsgreina og meðhöndla æxli og sjúkdóma, sem tengjast æðanýmyndun | |
AR020071A1 (es) | Anticuerpos que tienen una afinidad optimizada para un epitope caracteristico de dominio ed-b de la fibronectina, conjugados que contienen esos anticuerposy metodos terapeuticos para el tratamiento de la angiogenesis. | |
ATE165395T1 (de) | Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen | |
WO2004065547A3 (en) | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods | |
EA199800025A1 (ru) | Стойкие реагенты для получения радиофармпрепаратов | |
NO20006681D0 (no) | Fremgangsmåte ved tidlig diagnose av karsinomer | |
ATE460946T1 (de) | Gebrauch von bispezifischen antikörpern in diagnose und therapie | |
IL129299A0 (en) | Monoclonal antibodies antigens and diagnosis of malignant diseases | |
KR20170121215A (ko) | 암의 진단 및 치료를 위한 조성물 및 방법 | |
EP1064005A4 (en) | USE OF THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A TARGET IN THE DIAGNOSIS OF METASTASES | |
DE60014064D1 (de) | Einetenascin-c isoform als marker für neoplasmen | |
US20240002471A1 (en) | Compositions and Methods for Diagnosis and Treatment of Cancer | |
BG105030A (en) | Antibodies against ed-b domain of fibronectin, conjugates containing them, and their application for diagnostics and treatment of tumours and morbid conditions related to angiogenesis | |
IL129236A0 (en) | Monoclonal antibodies against a human act and serine protease complex | |
AU2002233278A1 (en) | Method and use of the cytosolic nadp-dependent malate-decarboxylase isoenzyme for identifying a malignant process, and a suitable test kit | |
SI1084145T1 (sl) | Protitelesa za ED-B domeno fibronektina, konjugati, ki jih vsebujejo, in njihova uporaba za diagnozo in terapijo tumorjev in bolezni povezanih z angiogenezo | |
BR9815776A (pt) | Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade | |
WO2000014537A3 (en) | Immunoconjugate for diagnosis of multidrug resistance |